A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
A phase 2 trial of Ficerafusp alfa, Pembrolizumab in head and neck squamous cell carcinoma, run by Bicara Therapeutics, now recruiting.
Overview
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC is a phase 2 interventional study registered as NCT07807163 by Bicara Therapeutics, with 160 participants planned, started 2026-09 and due to reach its primary completion in 2028-03. Interventions recorded: Ficerafusp alfa, Pembrolizumab (KEYTRUDA®). Conditions listed: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Setting
A Multicenter, Open-label, Randomized Phase 2 Study Evaluating Continuous Weekly Dosing of Ficerafusp Alfa (BCA101) in Combination With Pembrolizumab Versus an Alternative Ficerafusp Alfa Dosing Regimen for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase
Phase 2
Sponsor
Bicara Therapeutics
Registry
Enrolled
160